ACAD ACADIA Pharmaceuticals Inc.
22.93
+0.67 (+3%)
Previous Close
22.26
Open
22.44
Price To Book
12.81
Market Cap
2867959592
Shares
125,074,557
Volume
1,404,949
Short Ratio
Av. Daily Volume
1,708,285
NewsSee all news
- ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
- What's in the Cards for Bausch Health (BHC) Q4 Earnings?
- 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
- New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
- ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
SEC filingsSee all SEC filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604876
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594507
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582893
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19581938
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19561962
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 2 data released October 31, 2018 - noted overall primary endpoint met BUT did not benefit placebo in re-randomized stage.
Pimavanserin - CLARITY
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 initiated November 2016. Enrolment to be completed 2H 2019.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Latest News
- ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
- What's in the Cards for Bausch Health (BHC) Q4 Earnings?
- 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
- New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
- ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
- Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
- Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
- Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
- See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
- Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
- Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
- Is a Beat in Store for Vertex (VRTX) This Earnings Season?
- MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
- Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals
- Will ACADIA Pharmaceuticals Continue to Surge Higher?
- Does ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) CEO Pay Compare Well With Peers?
- Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
- Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors (ACAD)
SEC Filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604876
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594507
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582893
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19581938
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19561962
- SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181217615
- 8-K - Current report 181206460
- 424B5 - Prospectus [Rule 424(b)(5)] 181206443
- 424B5 - Prospectus [Rule 424(b)(5)] 181201185
- S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181200928